Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial

Background: Advances in therapeutic drugs have increased life-expectancies for HIV-infected individuals, but the need for an effective vaccine remains. We assessed safety and immunogenicity of HIV-1 vaccine, Trimer 4571 (BG505 DS-SOSIP.664) adjuvanted with aluminum hydroxide (alum), in HIV-negative...

Description complète

Détails bibliographiques

Auteurs principaux:	Katherine V. Houser, Martin R. Gaudinski, Myra Happe, Sandeep Narpala, Raffaello Verardi, Edward K. Sarfo, Angela R. Corrigan, Richard Wu, Ro Shauna Rothwell, Laura Novik, Cynthia S. Hendel, Ingelise J. Gordon, Nina M. Berkowitz, Cora Trelles Cartagena, Alicia T. Widge, Emily E. Coates, Larisa Strom, Somia Hickman, Michelle Conan-Cibotti, Sandra Vazquez, Olga Trofymenko, Sarah Plummer, Judy Stein, Christopher L. Case, Martha Nason, Andrea Biju, Danealle K. Parchment, Anita Changela, Cheng Cheng, Hongying Duan, Hui Geng, I-Ting Teng, Tongqing Zhou, Sarah O'Connell, Chris Barry, Kevin Carlton, Jason G. Gall, Britta Flach, Nicole A. Doria-Rose, Barney S. Graham, Richard A. Koup, Adrian B. McDermott, John R. Mascola, Peter D. Kwong, Julie E. Ledgerwood
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2022-06-01
Collection:	EClinicalMedicine
Sujets:	HIV-1 Vaccine Trimer 4571 BG505 DS-SOSIP.664 Phase 1 clinical trial NIH
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2589537022002073
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!